Compare Dishman Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PFIZER - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PFIZER DISHMAN PHARMA/
PFIZER
 
P/E (TTM) x 25.1 49.3 50.9% View Chart
P/BV x 3.3 8.2 40.9% View Chart
Dividend Yield % 0.7 0.4 159.0%  

Financials

 DISHMAN PHARMA   PFIZER
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PFIZER
Mar-19
DISHMAN PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3743,840 9.8%   
Low Rs1292,080 6.2%   
Sales per share (Unadj.) Rs197.8455.0 43.5%  
Earnings per share (Unadj.) Rs21.293.8 22.6%  
Cash flow per share (Unadj.) Rs34.7109.4 31.7%  
Dividends per share (Unadj.) Rs2.0022.50 8.9%  
Dividend yield (eoy) %0.80.8 104.6%  
Book value per share (Unadj.) Rs179.9658.2 27.3%  
Shares outstanding (eoy) m80.6945.75 176.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.36.5 19.6%   
Avg P/E ratio x11.931.6 37.6%  
P/CF ratio (eoy) x7.227.1 26.8%  
Price / Book Value ratio x1.44.5 31.1%  
Dividend payout %9.424.0 39.3%   
Avg Mkt Cap Rs m20,306135,420 15.0%   
No. of employees `0000.82.6 31.5%   
Total wages/salary Rs m5,3553,238 165.4%   
Avg. sales/employee Rs Th19,252.77,911.4 243.4%   
Avg. wages/employee Rs Th6,459.51,230.9 524.8%   
Avg. net profit/employee Rs Th2,064.11,630.7 126.6%   
INCOME DATA
Net Sales Rs m15,96120,815 76.7%  
Other income Rs m2651,674 15.9%   
Total revenues Rs m16,22622,489 72.2%   
Gross profit Rs m4,1035,712 71.8%  
Depreciation Rs m1,091714 152.8%   
Interest Rs m94473 1,295.5%   
Profit before tax Rs m2,3346,599 35.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,309 27.0%   
Profit after tax Rs m1,7114,291 39.9%  
Gross profit margin %25.727.4 93.7%  
Effective tax rate %26.735.0 76.4%   
Net profit margin %10.720.6 52.0%  
BALANCE SHEET DATA
Current assets Rs m11,01827,167 40.6%   
Current liabilities Rs m9,5178,917 106.7%   
Net working cap to sales %9.487.7 10.7%  
Current ratio x1.23.0 38.0%  
Inventory Days Days11068 162.9%  
Debtors Days Days3530 115.7%  
Net fixed assets Rs m16,3048,862 184.0%   
Share capital Rs m161458 35.3%   
"Free" reserves Rs m12,90729,656 43.5%   
Net worth Rs m14,51630,113 48.2%   
Long term debt Rs m4,18925 16,757.6%   
Total assets Rs m29,80539,400 75.6%  
Interest coverage x3.591.5 3.8%   
Debt to equity ratio x0.30 34,764.8%  
Sales to assets ratio x0.50.5 101.4%   
Return on assets %8.911.1 80.5%  
Return on equity %11.814.2 82.7%  
Return on capital %17.522.1 79.2%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,952428 1,156.1%   
Fx outflow Rs m697786 88.6%   
Net fx Rs m4,255-358 -1,188.1%   
CASH FLOW
From Operations Rs m2,786978 284.9%  
From Investments Rs m-1,529351 -435.3%  
From Financial Activity Rs m-941-1,099 85.7%  
Net Cashflow Rs m316231 137.1%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 3.7 7.5 49.3%  
FIIs % 12.7 4.9 259.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 23.7 93.2%  
Shareholders   46,261 85,207 54.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA  NOVARTIS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 296 Points Higher; Coal India, UPL & Hindalco Surge Over 6%(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS